{
    "nctId": "NCT03393117",
    "briefTitle": "Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction",
    "officialTitle": "Prospective, Randomized, Blinded Comparison of Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Unilateral, Immediate Breast Reconstruction",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "total post-operative narcotic utilization",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients scheduled to have a unilateral, immediate breast reconstruction\n\nExclusion Criteria:\n\n* Pregnant\n* Concurrent or recent medical condition that could interfere with study participation including:\n\n  * Hepatitis\n  * Alcohol/substance abuse\n  * Uncontrolled psychiatric disorders\n  * Known allergy\n  * Contraindication to amide-type local anesthetics, opioids, or propofol.\n* Body weight of less than 50 kg\n* Participated in another study involving an investigational medication within the prior 30 days\n* Taking analgesics (i.e., nonsteroidal anti-inflammatory drugs, acetaminophen, or opioids), antidepressants, or glucocorticoids within the 3 days before surgery.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}